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PROTOCOL

Open Access

Hepatitis C virus infection among HIV-positive
men who have sex with men: protocol for a
systematic review and meta-analysis
Holly Hagan1*, Joshua Neurer2, Ashly E Jordan1, Don C Des Jarlais3, Jennifer Wu4, Kirk Dombrowski5, Bilal Khan6,
Ronald Scott Braithwaite4 and Jason Kessler4

Abstract
Background: Outbreaks of hepatitis C virus (HCV) infection have been reported in HIV-positive men who have sex
with men (MSM) in North America, Europe and Asia. Transmission is believed to be the result of exposure to blood
during sexual contact. In those infected with HIV, acute HCV infection is more likely to become chronic, treatment
for both HIV and HCV is more complicated and HCV disease progression may be accelerated. There is a need for
systematic reviews and meta-analyses to synthesize the epidemiology, prevention and methods to control HCV
infection in this population.
Methods/design: Eligible studies will include quantitative empirical data related to sexual transmission of HCV in
HIV-positive MSM, including data describing incidence or prevalence, and associations between risk factors or
interventions and the occurrence or progression of HCV disease. Care will be taken to ensure that HCV transmission
related to injection drug use is excluded from the incidence estimates. Scientific databases will be searched using a
comprehensive search strategy. Proceedings of scientific conferences, reference lists and personal files will also be
searched. Quality ratings will be assigned to each eligible report using the Newcastle–Ottawa scale. Pooled
estimates of incidence rates and measures of association will be calculated using random effects models.
Heterogeneity will be assessed at each stage of data synthesis.
Discussion: HIV-positive MSM are a key HCV-affected population in the US and other high-income countries. This
review seeks to identify modifiable risk factors and settings that will be the target of interventions, and will consider
how to constitute a portfolio of interventions to deliver the greatest health benefit. This question must be
considered in relation to the magnitude of HCV infection and its consequences in other key affected populations,
namely, young prescription opioid users who have transitioned to illicit opiate injection, and older injection drug
users among whom HCV prevalence and incidence are extremely high. This review is part of a series of systematic
reviews and meta-analyses that will synthesize the evidence across all these population groups and develop
recommendations and decision tools to guide public health resource allocation.
Trial registration: PROSPERO registration number: CRD42013006462
Keywords: Hepatitis C virus, Men who have sex with men, HIV infection, Epidemiology, Systematic review
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Background
Introduction

There are an estimated 8.4 million men who have sex
with men (MSM) in the US [1]; 16% are HIV positive
[2]. Since 2000, there have been multiple reports of outbreaks of sexually transmitted acute hepatitis C virus
(HCV) infection in HIV-positive MSM in the US,
Canada, Europe, Japan and Australia [3]. The evidence
points to blood as the medium of HCV exposure in sexual transmission [4,5]. A recurring context for transmission is group sex settings, where multiple individual
risks converge including serosorting on the basis of
HIV-positive status and sexual practices that cause
trauma to mucosal surfaces and rectal bleeding [6-9].
In HIV-infected patients, acute HCV infection is more
likely to become persistent, and HCV treatment is less
likely to result in cure [10]. The risk of advanced liver fibrosis is elevated twofold in co-infected patients and
HIV treatment is complicated in the presence of HCV-
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related liver damage [11]. Liver disease and hepatocellular carcinoma have become leading causes of death in
HIV-infected individuals [12], and the risk of hepatocellular carcinoma is three to eight times higher among coinfected vs HCV mono-infected patients [13]. In general,
HIV/HCV co-infection is characterized by decreased response to therapies and increased rates of both HIV and
HCV disease progression [14].
Current recommendations to prevent HCV in HIVpositive MSM center on detecting acute infection through
screening for elevated liver enzymes every three months
and providing immediate HCV treatment to HCV RNA
positive patients to prevent chronic HCV infection [10,15].
Early treatment of acute HCV infection in HIV-positive patients is associated with high response rates [16]. New
direct-acting antiviral treatments for HCV infection have
been shown to increase the likelihood of cure, and the
course of treatment may be substantially shorter than with
older regimens [17]. However, high rates of reinfection

Figure 1 Scope of the systematic review. The figure shows the disease state (blue rectangles), interventions (orange diamonds) and factors
influencing state transitions (green ovals) in sexual HCV transmission and natural history of HIV-positive men who have sex with men. HCV,
hepatitis C virus; MSM, men who have sex with men.
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post-HCV treatment in HIV-positive MSM have been reported [18], and the cost of treatment, particularly with the
new direct-acting antivirals, may limit the feasibility of this
approach to HCV control [19].
In this systematic review, we will synthesize existing
data describing rates of sexual HCV transmission in
HIV-positive MSM and factors associated with transmission, rates of reinfection post-HCV treatment and the
effects of interventions to prevent or treat HCV infection. Figure 1 shows the logic model guiding this review.
Estimates derived from the review will be used to inform
simulations of the effect (and the cost) of early treatment
and behavioral and other interventions on HCV transmission and natural history in HIV-positive MSM. This
systematic review and meta-analysis and related modeling are part of the HCV Synthesis Project, which is
funded to develop guidance and recommendations for
HCV control strategies for the United States.
Previous reviews

HCV infection related to drug use has been addressed in
several previous systematic reviews. These have covered
HCV epidemiology in people who smoke or inhale drugs
such as heroin, cocaine or crack [20], HCV epidemiology
in people who inject drugs (PWID) [21,22], prevention and
treatment of HCV infection in PWID [23-26], and heterosexual HCV transmission [27]. We are aware of only
one systematic review describing HCV incidence in HIVpositive MSM; this review included 12 eligible articles [28].
HCV incidence rates among HIV-positive MSM ranged
from 0 to 41.7/1,000 person years (PY), with a pooled rate
of 6.08/1,000 PY (95% CI 5.18 to 6.99). A limitation of this
review was that it did not describe a method to screen or
classify studies in relation to sexual vs drug-related routes
of exposure to HCV. Indeed, the inadvertent inclusion of
HIV-positive MSM injectors may overestimate HCV seroconversion rates, because parenteral exposure is a much
more efficient route of HCV transmission [29]. We believe
that there have been no previous reviews synthesizing the
risk of reinfection post-HCV treatment, which is highly
relevant to the design of HCV control programs. Thus, the
systematic review proposed here will make a unique contribution to our understanding of sexual HCV transmission, its consequences and control in HIV-positive MSM.

Methods/design
Design and scope

This study will consist of a systematic review and metaanalysis of the epidemiology, natural history and methods
to control sexually transmitted HCV infection in HIVpositive MSM, as shown in Figure 1. Reports published or
available from 1 January 1990 (when HCV testing became
available) through 31 December 2013 will be included.
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Criteria for considering studies
Inclusion and exclusion criteria

We will include published and unpublished quantitative
epidemiologic and intervention studies using crosssectional, cohort (prospective and retrospective) and case–
control designs. Epidemiologic studies will report HCV
prevalence, incidence or risk factor analyses. Intervention
studies will report on the effects of interventions to prevent or treat HCV infection in this population. Studies
must include male individuals who are HIV-positive and
who reported having sex with other men. We will not include data related to HIV-negative MSM or heterosexual
men. An explicit mention that HIV-positive MSM using
injection drugs were excluded from the analysis will be
required because such individuals likely acquired HCV
infection through the use of contaminated injection
equipment rather than from sexual exposure. In studies
that included both injecting and non-injecting MSM,
separate estimates must be provided for non-injectors.
Studies among incarcerated persons will also be excluded, as infection rates and circumstances surrounding
transmission are not likely to be generalizable to the
broader population of HIV-positive MSM. Epidemiologic
studies that enrolled HIV-positive MSM from settings
where infection, exposure or disease progression rates
were likely to be biased, such as in hepatology or gastroenterology clinics, or in sexually transmitted infection
clinics, will be included but this will be noted in the
quality ratings. All ages and individuals from any racial
or ethnic group will be included. The search will include
English-language reports available from 1 January 1990
through 31 December 2013.
Outcome measures

All reports must state that laboratory tests were used to
ascertain HCV infection among subjects. Data reports that
used self-reports or questionnaires to identify HCV status
will be excluded. Rates of acute HCV infection or seroconversion, and reinfection with HCV post-HCV treatment in
HIV-positive MSM will be included. We define subjects
with ‘HCV seroconversion’ or ‘acute HCV’ as those who
have been screened and tested positive for HCV antibodies
(serology) or RNA within 12 months of previously testing
negative. We adopted the European AIDS Treatment
Network (European NEAT) Acute Hepatitis C Infection
Consensus Panel criteria [30].
The preferred criteria are seroconversion or positive
HCV RNA and a documented negative HCV RNA or
negative HCV antibody in the previous 12 months. Alternative criteria include positive HCV RNA and an elevated
ALT with or without other clinical signs of hepatitis.
Studies using the preferred criteria will be given higher
quality ratings than those that use the alternative criteria.
HCV reinfection will be defined as newly detectable HCV
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RNA following clearance of the infection in response to
treatment of HCV infection.
Exposure measures

Exposures of interest include sexual practices that are
hypothesized to increase the risk of blood exposure and
thereby facilitate HCV transmission. These include unprotected receptive and insertive anal sex, practices that
can damage the genital and anal mucosal surfaces such
as fisting or ‘rough sex’, participation in group sex events
and prolonged periods of sexual activity [8]. Age, race/
ethnicity, calendar time, geographic location, substance
use and other characteristics of the study sample will be
collected as potential confounders or modifiers of the influence of exposures on HCV infection. Interventions of
interest include behavioral interventions to reduce sexual risk behavior, condom distribution programs, liver
enzyme screening and early treatment, and others that
may emerge.
Search strategy

The search strategy was developed in consultation with
a medical librarian. The PubMed, EMBASE and BIOSIS
databases will be searched using terms that cover the
themes hepatitis C virus, men who have sex with men,
transmission, prevention and treatment. Additional reports will be located by searching conference proceedings (e.g., the American Association for the Study of
Liver Diseases, European Association for the Study of
the Liver, International Conference on HIV/AIDS and
Conference on Retroviruses and Opportunistic Infections), investigators’ personal files, and reference lists of
reviews and related articles.
Screening and data collection

Reports obtained via the search strategy (abstracts and
full-text articles) will be imported into Endnote X6 [31]
and duplicates will be deleted. Reasons for exclusion will
be recorded. Relevant data will be abstracted onto a
paper instrument adapted from those used in a series of
prior systematic reviews of HCV infection led by the
first author [32]. Once this is complete, the data will be
entered into a Microsoft Access database. Data to be abstracted will include citation information, study years
and locations, study design, methods and sites used to
recruit study participants, method used to determine
HCV infection and reinfection, types of interventions
studied, sample size and demographic, and other characteristics of the study sample (e.g., mucosally traumatic
sexual practices and sex under the influence of drugs).
Crude and adjusted measures of association (odds ratios, relative risks, hazard ratios, etc.) between disease
outcomes (HCV infection and reinfection) and relevant
exposures, confounding and moderating factors will be
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recorded. For those reports that are missing key data of
interest to this systematic review but were thought potentially to have collected these data, the corresponding
authors will be contacted.
Quality assurance

Screening and data abstraction will be carried out by
staff with graduate training in research methodology and
additional training in HCV epidemiology, and systematic
review and meta-analysis methods. A pilot study will be
carried out to test and refine procedures for screening
and data abstraction. Two staff will independently screen
and code a subset of articles retrieved using the search
criteria and will compare results. Discrepancies between
the results will be discussed and the protocol will be revised to clarify procedures. This process will be repeated
until consensus is reached. Reports that were deemed ineligible will be reviewed by the project director (AEJ) to
ensure that no eligible reports are excluded. In addition,
all coding will be reviewed for accuracy and completeness by the project director and the principal investigator (HH). Weekly staff meetings will discuss and resolve
any issues that may arise. A written study manual will be
developed to guide the process and to record special
cases and their resolution.
Study quality and critical appraisal

In this synthesis, bias in the included studies may arise in
the form of selection bias, misclassification of exposure or
outcome, and confounding due to non-comparability of
the groups being compared. The quality rating procedure
that will be employed is based on the Newcastle–Ottawa
Scale, which assigns quality ratings to studies in relation
to these threats to internal validity (selection bias, misclassification and non-comparability) [33]. Some types of
bias will be addressed through screening of reports for eligibility. For example, we will exclude reports that may
have misclassified HCV exposure (sexual vs injection related) by failing to exclude MSM who inject drugs from
their analyses. Eligibility screening also will address potential misclassification of the outcome (e.g., acute or recent
vs chronic HCV infection). In addition to the Newcastle–
Ottawa Scale, publication bias will be examined by
comparing mean effect sizes between published and
unpublished studies and by the use of funnel plots [34].
Selection bias

The potential for selection bias in case–control studies
will be evaluated in relation to whether similar and adequate methods were used to classify case vs control status, and whether cases and controls arose from the same
underlying population (in other words, ‘If controls had
acquired HCV infection or had progressed toward cirrhosis, would they appear as cases in this study?’). In
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cohort studies, selection bias will be judged in relation
to whether ascertaining exposure or selection of the exposed cohort was related to likelihood of HCV infection,
and whether methods were adequate in assuring that
HCV infection was not present at the start of the cohort
study (see European NEAT’s preferred criteria discussed
above).
Comparability

Comparability of cases and controls refers to whether
matching or adjustment for confounding (differences in
the distribution of factors across cases and controls that
could bias estimates of association) was carried out. In
cohort studies, comparability refers to whether the assessment of the association between exposure and HCV
infection adjusted for important differences between the
exposed and unexposed cohorts.
Misclassification

In case–control studies, classification of cases and controls with respect to exposure must be unbiased, and
using the same method to ascertain exposure for cases
and controls is preferred. Ascertainment of exposure
(factors related to sexual HCV transmission or progression) also relates to the extent to which reliable methods
were used to determine that HIV-positive MSM were
not also injection drug users. In cohort studies, misclassification of the outcome (e.g., acute or recent HCV
infection) will be addressed as part of the eligibility
screening. Studies using the European NEAT alternative
criteria (described above [30]) will be given lower quality
ratings.
Data analysis

Synthesis will begin with the search for homogeneous
subsets within sets of studies, followed by meta-analysis
and calculation of summary estimates within the homogeneous subsets. Evidence of heterogeneity will be evaluated at each step in the analysis to distinguish between a
true variation of effects and heterogeneity due to other
differences. Effect measures reported as hazards ratios,
risk ratios or relative risks will be transformed into odds
ratios using standard methods [35]. Forest plots will also
be used to assess underlying heterogeneity in relation to
covariates and quality ratings [36-38].
Some statistical heterogeneity in a meta-analysis is inevitable due to the methodological diversity of the studies. We will use Cochran’s Q statistic [37] to determine
whether observed heterogeneity is compatible with
chance, and quantify variability using the I2 statistic
[39]. We will take I2, the τ-statistic (variability due to
inter-study variance), as well as methodological, study
quality and other differences into consideration in determining whether to pool estimates. Effect size estimates
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will be combined using standard meta-analytic techniques
in the form of pooled odds ratios and their 95% confidence intervals [40]. We will use random effects calculations whenever possible [41]. Potential moderator effects
will be tested using meta-regression [42,43].

Discussion
This systematic review and meta-analysis will critically
assess the evidence related to sexual HCV transmission
in a key affected population – HIV-positive MSM. It is
anticipated that this review will identify modifiable behavioral risk factors and settings, which will be the target
of interventions to control transmission. These, along
with estimates of the range and magnitude of HCV
transmission in this population, will be key inputs to
simulations that will address the question of how to constitute a portfolio of interventions so as to deliver the
greatest health benefit given a particular budget.
During the past decade, clusters of HCV infection in 15
to 24 year olds who have transitioned from abuse of prescription opioids to illicit opiate injection have been reported throughout the US [44,45]. As the epidemic of
abuse of prescription opioids matures [46], it will likely
serve as a persistent source of new injectors, and HCV incidence in new injectors may exceed 40/100 PY [47,48].
The parallel emergence of outbreaks of HCV infection in
prescription opioid users and HIV-positive MSM raises
important and urgent questions regarding how to allocate
scarce public health resources to control HCV in the US.
Early reviews reported the median HCV incidence in
HIV-positive MSM was 6/1,000 PY [28]. Furthermore,
HCV infection is hyperendemic in older people who inject
or have ever injected drugs (PWID), with incidence rates
between 10/100 PY to 40/100 PY throughout the world.
The median prevalence in PWID in the US is estimated to
be 65% [21,22]. Thus, an effective HCV control strategy
must prioritize PWID. The HCV Synthesis Project will
conduct a series of systematic reviews and meta-analyses
to synthesize the evidence across all three of these population groups and, in collaboration with key community
stakeholders, will develop recommendations and decision
tools to guide public health policymakers toward an effective and feasible program of HCV control.
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